Enzyvant and Altavant have announced plans for a merger, which will take on the name of the former. The new company will have a facilities to manufacture regenerative medicines for rare diseases, particularly in immunology and cardiopulmonology. The combined Envyzant intends to build on its track record in the rare disease therapeutics space.
According to Emily Kimber, “Enzyvant received approval from the US Food and Drug Administration in October 2021 for its first commercial product, Rethymic (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for immune reconstitution in paediatric patients with congenital athymia, a disease characterised by the absence of a functioning thymus.”
To read more, click here.
(Source: PM Live, December 8th, 2022)